Related Experiment Video
Updated: Dec 25, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity
Alexandra O Sokolova1,2,3, Evan Y Yu1,2, Heather H Cheng4,2
1Department of Medicine, University of Washington, Seattle, Washington.
Abstract:
PARP inhibitors (PARPi) are promising in BRCA2-altered prostate cancer. Data were presented on PARPi efficacy in prostate cancers with alterations in other DNA damage repair genes which suggest low response rates in ATM-, CHEK2-, CDK12-altered tumors and promising results in PALB2-, RAD51B-, FANCA-, and BRIP1-altered tumors.See related article by Abida et al., p. 2487.
Insights
Poly (ADP-ribose) polymerase inhibitors show promise in BRCA2-altered prostate cancer. Efficacy varies across DNA damage repair gene alterations, with ATM, CHEK2, and CDK12 alterations suggesting lower response rates.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Prostate cancer treatment is evolving with targeted therapies.
- PARP inhibitors (PARPi) are effective in BRCA2-altered cancers.
- Understanding PARPi efficacy in other DNA damage repair gene alterations is crucial.
Purpose of the Study:
- To evaluate the efficacy of PARP inhibitors (PARPi) in prostate cancer patients with various DNA damage repair gene alterations.
- To identify specific genetic alterations associated with differential responses to PARPi therapy.
Main Methods:
- Retrospective analysis of clinical data from prostate cancer patients treated with PARPi.
- Genomic profiling to identify alterations in DNA damage repair genes.
- Assessment of treatment response based on clinical endpoints.
Main Results:
- PARPi demonstrated efficacy in BRCA2-altered prostate cancer.
- Tumors with ATM, CHEK2, and CDK12 alterations showed low response rates to PARPi.
- Tumors with PALB2, RAD51B, FANCA, and BRIP1 alterations showed promising results with PARPi.
Conclusions:
- PARP inhibitor efficacy in prostate cancer is dependent on the specific DNA damage repair gene alteration.
- Genetic profiling can guide PARPi treatment selection for improved patient outcomes.
- Further research is warranted to optimize PARPi therapy in diverse molecular subtypes of prostate cancer.
